Investigation Of Relationship Between Adiponectin With Insulin Resistance And Metabolism Of Blood Lipid

[Objective] To investigate the serum adiponectin concentration in healthy people and patiens with metabolic syndrome and the relationship between adiponectin with age, sex, body mass index, waist-to-hip ratio, insulin resistance index and lipid profile. To illuminate the influence of lowering lipid therapy on serum adiponectin level.[Methods] The serum adiponectin concentrations in 87 healthy people and 137 patients with metabolic syndrome were measured by radioimmunoassay. The body height, body weight, body mass index, waist circumference, hip circumference, waist-to-hip ratio, fasting plasma glucose level, fasting plasma insulin level and lipid profile of these people were measured at the same time in order to study the relationships between the serum adiponectin levels with these data. 42 type 2 diabetic patients without macrovascular disease who were diagnosis recently were divided into 2 groups. One group received the therapy of lowering plasma glucose and blood pressure, the other received the therapy of lowering plasma glucose, blood pressure and lipid profile. After 9 months, the serum adiponectin concentrations were measured again.[Results] 1. The average concentrations of the serum adiponectin in healthy people were 8.34±4.72μg/ml, and the serum adiponectin levels in female(9.92±4.62μg/ml) were higher than those in male(6.99±4.43μg/ml, P<0.01). The serum adiponectin levels were negatively correlated with body weight, body mass index, waist circumference, hip circumference, waist-to-hip ratio, systolic blood pressure, low-density lipoprotein-cholesterol, fasting plasma insulin level and insulin resistance index which was assessed by homoeostasis model assessment and positively correlated with high-density lipoprotein -cholesterol. Stepwise multiple regression analysis revealed that waist-to-hip ratio and fasting plasma insulin level were independently correlated with the serum adiponectin level.2. The serum adiponectin concentrations in patients with metabolic syndrome (5.75±2.89μg/ml) were lower than those in healthy people (P<0.01), and the serum adiponectin levels in female (6.56±2.76μg/ml) were higher than those in male (5.12±2.85μg/ml, P<0.01). The serum adiponectin levels of patients with metabolic syndrome were negatively correlated with body height, body weight, body mass index, triglycerides and insulin resistance index which was assessed by homoeostasis model assessment. Stepwise multiple regression analysis revealed that body weight was the only factor influencing the serum adiponectin level. There were significant differences in the serum adiponectin levels in different groups. Factorial experiment revealed that the serum adiponectin concentrations in patients with coronary heart disease or obesity decreased significantly.3. The serum adiponectin concentrations were significantly increased in group in which type 2 diabetic patients without macrovascular disease received lowering plasma glucose, blood pressure and lipid therapy.[Conclusion] Adiponectin is a novel, adipose-specific protein which is present abundantly in the circulation in healthy people. It is influenced by sex, fat and coronary heart disease. The improvement in lipid profile will increase the serum adiponectin levels which is likely one of the mechanisms that adiponectin prevent the development of macrovascular disease of type 2 diabetes mellitus.